Pharmaceutical Industries: Merck & Co., Term Paper

Open, View, and/or
Download this Document

Total Length: 959 words ( 3 double-spaced pages)

Total Sources: 1+

Page 1 of 3

38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T

There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines. The fourth-quarter 2004 EPS anticipation is stated to be $0.48 to $0.53, which includes the impact of approximately "$700 to $750 million foregone sales of VIOXX. The result is anticipation by Merck for EPS guidance (2004 full-year) of $2.59 to $2.64. These amounts include withdrawal impact and next years negative affects of the DPS by $0.50 to $0.55."

Merck & Co., Inc. announced in a recent report that they had made submission to the U.S. Food and Drug Administration (FDA) PROQUAD, which is a vaccine for children. The composition of the vaccine is a cocktail like mixture of the chickenpox, measles, mumps and rubella vaccine. Also expected by Merck for submission is 'muraglitazar' which is the "first-in-class 'dual PPAR agonist for Type 2 diabetes treatment in collaboration with Bristol-Myers Squibb."(Merck & Co, Inc. 2004)

In a December 7, 2004 Press Release the announcement made by the Board of Directors of Merck & Co., Inc. that a "Special Board Committee to review the company's actions prior to Merck's voluntary withdrawal of VIOXX, to act for the Board in responding to shareholder litigation matter related to the withdrawal of VIOXX and to advise the Board with respect to any action that should be taken as a result of the review.

Stuck Writing Your "Pharmaceutical Industries: Merck & Co.," Term Paper?

View All Our Example Pharmaceutical Industries: Merck & Co., Term Paper

Have A Custom Example Essay Written

"

IV. Competitive Countries:

Competitive Countries in the Pharmaceutical Industry are with the United States as the top competititor with 48.20% of global sales and a 2000 sales figure of $152.9 billion and a 14% year-over-year growth. Europe follows the United States with 23.7% of global sales for the sum of %75.3 billion and an 8% year-over-year growth. Japan is the third top competitor with 16.2% of global sales in the amount of $51.5 billion and a 3% year-over- year growth followed by Latin America who claimed 6% of global sales for the sales figure of $18.9 billion and 9% year-over year growth. Asia, Africa and Australia follow Latin America with 5.9% of global sales equaling $18.7 billion and a 1-% year-over-year growth. The total sales for the pharmaceutical industry in 2000 were $317.20 billion with a 10% year-over-year growth.

Conclusion:

The pharmaceutical industry is an industry that will continue to be in demand especially due to the need for vaccines due to re-emergent diseases in the form of Tuberculosis and others which have emerged again that had been deemed extinct......

Show More ⇣

     Open the full completed essay and source list


OR

     Order a one-of-a-kind custom essay on this topic


sample essay writing service

Cite This Resource:

Latest APA Format (6th edition)

Copy Reference
"Pharmaceutical Industries Merck & Co " (2004, December 13) Retrieved July 8, 2025, from
https://www.aceyourpaper.com/essays/pharmaceutical-industries-merck-co-60158

Latest MLA Format (8th edition)

Copy Reference
"Pharmaceutical Industries Merck & Co " 13 December 2004. Web.8 July. 2025. <
https://www.aceyourpaper.com/essays/pharmaceutical-industries-merck-co-60158>

Latest Chicago Format (16th edition)

Copy Reference
"Pharmaceutical Industries Merck & Co ", 13 December 2004, Accessed.8 July. 2025,
https://www.aceyourpaper.com/essays/pharmaceutical-industries-merck-co-60158
   

Open, View, and/or
Download this Document
order custom essay example